Cargando…

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C

The recent introduction of direct-acting antiviral drugs (DAAs) for treatment of the hepatitis C virus (HCV) has greatly improved the management of HCV for infected patients. These viral protein inhibitors act rapidly, allowing HCV clearance and increasing the sustained virological response rates. H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aggeletopoulou, Ioanna, Konstantakis, Christos, Manolakopoulos, Spilios, Triantos, Christos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487495/ https://www.ncbi.nlm.nih.gov/pubmed/28706414 http://dx.doi.org/10.3748/wjg.v23.i24.4317

Ejemplares similares

Epidemiology of hepatitis C in Greece
por: Triantos, Christos, et al.
Publicado: (2016)

Role of band ligation for secondary prophylaxis of variceal bleeding
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2018)

Role of NLRP3 inflammasome in inflammatory bowel diseases
por: Tourkochristou, Evanthia, et al.
Publicado: (2019)

Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2018)

The Impact of Host Metabolic Factors on Treatment Outcome in Chronic Hepatitis C
por: Savvoula, Savvidou, et al.
Publicado: (2012)

Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice
por: Papatheodoridi, Μargarita, et al.
Publicado: (2017)

Νon-invasive screening for esophageal varices in patients with liver cirrhosis
por: Karatzas, Andreas, et al.
Publicado: (2018)

Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs
por: Siakavellas, Spyros, et al.
Publicado: (2021)

Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting
por: Koustenis, Kanellos Rafail, et al.
Publicado: (2020)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
por: Ghweil, Ali A, et al.
Publicado: (2019)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
por: Hong, Suk-Jin, et al.
Publicado: (2020)

Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals
por: Lee, Shou-Wu, et al.
Publicado: (2018)

Elastography for Hepatic Fibrosis Severity in Chronic Hepatitis B or C
por: Papageorgiou, Maria-Vasiliki, et al.
Publicado: (2011)

Prognostic significance of vitamin D receptor (VDR) gene polymorphisms in liver cirrhosis
por: Triantos, Christos, et al.
Publicado: (2018)

Aiming towards hepatitis C virus elimination in Greece
por: Papatheodoridis, George V., et al.
Publicado: (2019)

2197. Hepatitis B Reactivation in Patients with Malignancies Undergoing Treatment for Hepatitis C Infection with Direct-Acting Antivirals
por: Pritchard, Haley, et al.
Publicado: (2018)

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Molecular Mechanisms Underlying IL-33-Mediated Inflammation in Inflammatory Bowel Disease
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2022)

Nucleic acid vaccines: A taboo broken and prospect for a hepatitis B virus cure
por: Tsounis, Efthymios P, et al.
Publicado: (2021)

Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C
por: Manolakopoulos, Spilios, et al.
Publicado: (2016)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
por: Kim, Jin-Wook
Publicado: (2019)

Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Ramadan, Mohammad Said, et al.
Publicado: (2022)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Vitamin D–VDR Novel Anti-Inflammatory Molecules—New Insights into Their Effects on Liver Diseases
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2022)

miRNA Molecules—Late Breaking Treatment for Inflammatory Bowel Diseases?
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2023)

Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis
por: Kranidioti, Hariklia, et al.
Publicado: (2018)

Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis
por: Oh, Joo Hyun, et al.
Publicado: (2022)

Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors
por: Kranidioti, Hariklia, et al.
Publicado: (2015)

Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?
por: Adinolfi, Luigi Elio, et al.
Publicado: (2018)

The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection
por: Dawood, Reham M, et al.
Publicado: (2022)

The role of vitamin D receptor polymorphisms in the course of chronic hepatitis C infection
por: Tsounis, Efthymios P., et al.
Publicado: (2022)

Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2023)

Creeping Fat in Crohn’s Disease—Surgical, Histological, and Radiological Approaches
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2023)

Evaluation of fibrosis in chronic hepatitis C patients treated with direct-acting antivirals
por: Tufan, Ayse Gokcen, et al.
Publicado: (2020)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection
por: Liu, Chen-Hua, et al.
Publicado: (2017)

Editorial: Effective Direct-Acting Antiviral Treatments Support Global and National Programs to Eliminate Hepatitis C
por: Parums, Dinah V.
Publicado: (2023)

Is direct-acting antiviral treatment beneficial or harmful for patients with hepatitis C virus-related hepatocellular carcinoma?
por: Lee, Hye Won
Publicado: (2022)

Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Drazilova, Sylvia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n4ho9v8gadp5bg4ce71a2pcr4l